发明授权
US07358252B2 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
有权
4-（2-丁基氨基）-2,7-二甲基-8-（2-甲基-6-甲氧基吡啶-3-基）吡唑并[1,5-a] -1,3,5-三嗪，其对映异构体和 药学上可接受的盐作为促肾上腺皮质激素释放因子受体配体
![4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands](/docs/US/2008-04-15/US07358252B2/abs.jpg.600x600.jpg)
- 专利标题： 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
- 专利标题（中）： 4-（2-丁基氨基）-2,7-二甲基-8-（2-甲基-6-甲氧基吡啶-3-基）吡唑并[1,5-a] -1,3,5-三嗪，其对映异构体和 药学上可接受的盐作为促肾上腺皮质激素释放因子受体配体
-
申请号： US11593715申请日： 2006-11-07
-
公开(公告)号： US07358252B2公开(公告)日： 2008-04-15
- 发明人: Paul J. Gilligan
- 申请人： Paul J. Gilligan
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Pharma Company
- 当前专利权人： Bristol-Myers Squibb Pharma Company
- 当前专利权人地址： US NJ Princeton
- 代理机构： Hoffmann & Baron LLP
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; A61P25/02 ; A61P25/04 ; C07D403/12
![4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands](/abs-image/US/2008/04/15/US07358252B2/abs.jpg.150x150.jpg)
摘要：
Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
公开/授权文献
信息查询
